KORU Medical Systems, Inc. (KRMD)
| Market Cap | 149.14M -24.1% |
| Revenue (ttm) | 45.11M +22.4% |
| Net Income | -1.82M |
| EPS | -0.04 |
| Shares Out | 46.17M |
| PE Ratio | n/a |
| Forward PE | 745.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 143,839 |
| Open | 3.200 |
| Previous Close | 3.200 |
| Day's Range | 3.190 - 3.260 |
| 52-Week Range | 3.140 - 6.608 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 6.60 (+104.33%) |
| Earnings Date | Aug 5, 2026 |
About KRMD
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver,... [Read more]
Financial Performance
In 2025, KORU Medical Systems's revenue was $41.13 million, an increase of 22.23% compared to the previous year's $33.65 million. Losses were -$2.64 million, -56.52% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for KRMD stock is "Strong Buy." The 12-month stock price target is $6.6, which is an increase of 104.33% from the latest price.
News
KORU Medical Systems Slides: Corporate presentation
KORU Medical Systems has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Koru Medical price target lowered to $6 from $7 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker lowered the firm’s price target on Koru Medical (KRMD) to $6 from $7 and keeps a Buy rating on the shares following Q2 earnings, which exceeded…
KORU Medical Systems Earnings Call Transcript: Q2 2026
Q2 revenue grew 18% year-over-year to $12M, with strong domestic and international expansion and a return to positive net income. Guidance was narrowed due to international launch timing, but gross margin outlook was raised and long-term growth catalysts remain robust.
KORU Medical Systems Earnings release: Q2 2026
KORU Medical Systems released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
KORU Medical Systems Quarterly report: Q2 2026
KORU Medical Systems has published its Q2 2026 quarterly earnings report on August 5, 2026.
KORU Medical Systems Slides: Q2 2026
KORU Medical Systems has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
Kaskela Law LLC Announces Investigation of KORU Medical Systems, Inc. (KRMD) and Encourages Long-Term KRMD Shareholders to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating KORU Medical Systems, Inc. (Nasdaq: KRMD) (“KORU”) on behalf of the company's current shareholders.The investigation seeks to determine whet...
KORU Medical Systems to Report Second Quarter 2026 Financial Results on August 5, 2026
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializ...
KORU Medical Systems Slides: Investor presentation
KORU Medical Systems has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
KORU Medical Systems Presents Real World Data on the Benefits of the FreedomEDGE Syringe Infusion System in Infusion Clinics at the 51st Annual Oncology Nursing Society Congress
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume ...
Koru Medical reports Q1 revenue $11.77M, consensus $11.28M
16:14 EDT Koru Medical (KRMD) reports Q1 revenue $11.77M, consensus $11.28M
Koru Medical affirms FY26 revenue view $47.5M-$50M, consensus $48.52M
16:14 EDT Koru Medical (KRMD) affirms FY26 revenue view $47.5M-$50M, consensus $48.52M
KORU Medical Systems Earnings Call Transcript: Q1 2026
Q1 2026 delivered 22% revenue growth, strong domestic and international expansion, and improved profitability metrics. Guidance for the full year is reiterated, with expectations for continued growth, positive cash flow, and margin improvement as new markets and products ramp.
KORU Medical Systems Earnings release: Q1 2026
KORU Medical Systems released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
KORU Medical Systems Quarterly report: Q1 2026
KORU Medical Systems has published its Q1 2026 quarterly earnings report on May 6, 2026.
KORU Medical Systems Slides: Q1 2026
KORU Medical Systems has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
KORU Medical Systems Announces First Quarter 2026 Results
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026
MAHWAH, NJ--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercializat...
KORU Medical Systems Proxy statement: Proxy filing
KORU Medical Systems filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Koru Medical price target raised to $8 from $7 at B. Riley
B. Riley raised the firm’s price target on Koru Medical (KRMD) to $8 from $7 and keeps a Buy rating on the shares. Following the Q4 earnings report, B. Riley…
KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commerci...
KORU Medical Systems Earnings Call Transcript: Q4 2025
Revenue grew 22% year-over-year to $41.1M in 2025, with strong domestic and international gains, positive adjusted EBITDA, and cash flow. 2026 guidance projects 15%–22% revenue growth, continued profitability, and new product launches, amid a CEO transition.
KORU Medical Systems Annual report: Q4 2025
KORU Medical Systems has published its Q4 2025 annual report on March 12, 2026.